MedTrace Logo

Risk Markers in the Acute Coronary Syndromes

NCT00521976 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 871

Last updated 2021-09-29

Study results available
· View outcomes & findings →

Summary

The main aim of this trial is to assess the long-term prognostic value of different types of Factor XIIa in an unselected, single center series of 871 chest pain patients admitted to the emergency unit, employing blood samples collected at admission.

The second purpose of this study is to assess the incremental prognostic value of B-type natriuretic peptide (BNP) and high-sensitive C-reactive protein (hsCRP).

A third purpose of this study is to evaluate the prognostic impact of the Omega-3 Index which is a measure of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to other fatty acids in the erythrocyte membrane.

Conditions

Sponsors & Collaborators

  • Helse Vest

    collaborator OTHER

  • Axis-Shield, Dundee, UK

    collaborator UNKNOWN

  • Helse Stavanger HF

    lead OTHER_GOV

Principal Investigators

  • Dennis WT Nilsen, MD PhD FESC · Stavanger University Hospital, Dept. of Cardiology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Primary Completion
2005-12-31
Completion
2005-12-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00521976 on ClinicalTrials.gov